RGEN: Summary for Repligen Corporation - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 10:51am EST - Canadian Markets close in 5 hours and 9 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Repligen Corp. (RGEN)

At 10:21 EST: 4.84 USD

0.06 (1.26%)

MORE ON RGEN

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Repligen Corporation (NGM:RGEN) Delayed quote data

Last Trade:	4.84 USD
Trade Time:	10:21AM EST
Change:	0.06 (1.26%)
Prev Close:	4.78
Open:	4.75
Bid:	4.82 x 100
Ask:	4.85 x 3700
1y Target Est:	8.00

Day's Range:	4.71 - 4.84
52wk Range:	3.41 - 5.85
Volume:	4,222
Avg Vol (3m):	80,528.8
Market Cap:	148.87M
P/E (ttm):	3.69
EPS (ttm):	1.31
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add RGEN to Portfolio

Download Data

HEADLINES

•	"Black Friday" deals may not signal retail comeback
	Reuters (Mon, Nov 23)

•	REPLIGEN CORP Financials
	EDGAR Online Financials (Wed, Nov 11)

•	UPDATE - Regeneron, Sanofi, expand drug partnership
	at Reuters (Tue, Nov 10)

•	New Star Analyst Rankings for Repligen Corporation
	StarMine (Sun, Nov 8)

•	Repligen Corp. F2Q09 (Qtr. End 09/30/09) Earnings Call Transcript
	at Seeking Alpha (Thu, Nov 5)

•	Repligen Q2 Fiscal Year 2010 Earnings Call scheduled for 10:00 am ET today
	CCBN (Thu, Nov 5)

•	REPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
	EDGAR Online (Thu, Nov 5)

•	Repligen Q2 Fiscal Year 2010 Earnings Release - Before Market Open
	CCBN (Thu, Nov 5)

•	Repligen Reports Second Quarter Fiscal Year 2010 Financial Results
	PRNewswire (Thu, Nov 5)

•	Repligen to Present at the Merriman Curhan Ford 6th Annual Investor Summit Tuesday, November 10th, 1:40 p.m. EST
	PRNewswire (Tue, Nov 3)

More Headlines for RGEN...

ANALYST

EPS Est (next year) (Mar-08) :	N/A
EPS Est (in 2 years) (Mar-09) :	N/A
Avg Rec (current)*:	1.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Repligen Corporation, a biopharmaceutical company, engages in the research and development of therapeutics for the treatment of central nervous system diseases.

Full Company Profile

Add to Portfolio

Email to a Friend

•